CADRENAL THERAPEUTICS INC (CVKD) Forecast, Price Target & Analyst Ratings

NASDAQ:CVKD • US1276362076

Current stock price

5.42 USD
-0.31 (-5.41%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CADRENAL THERAPEUTICS INC (CVKD).

Forecast Snapshot

Consensus Price Target

Price Target
$34.68
+ 539.85% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 6, 2026
Period
Q4 / 2025
EPS Estimate
-$1.19
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$34.68
Upside
+ 539.85%
From current price of $5.42 to mean target of $34.68, Based on 7 analyst forecasts
Low
$25.25
Median
$32.64
High
$47.25

Price Target Revisions

1 Month
-4.67%
3 Months
-4.67%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for CVKD. The average price target is 34.68 USD. This implies a price increase of 539.85% is expected in the next year compared to the current price of 5.42.
The average price target has been revised downward by 4.67% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CVKD Current Analyst RatingCVKD Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

CVKD Historical Analyst RatingsCVKD Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
CVKD was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CVKD.
In the previous month the buy percentage consensus was at a similar level.
CVKD was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-05-16HC Wainwright & Co.Reiterate Buy -> Buy
2024-11-11HC Wainwright & Co.Maintains Buy -> Buy
2024-06-06HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-09HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-14HC Wainwright & Co.Reiterate Buy -> Buy
2023-12-18Noble Capital MarketsInitiate Outperform
2023-11-20HC Wainwright & Co.Initiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 6, 2026
Period
Q4 / 2025
EPS Estimate
-$1.19
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
56.63%
Number of Analysts
5

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
3.72%
EPS (3 Months)
15.78%

Next Earnings Summary

CVKD is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -1.19 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2025 - 2029

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2021 2022 2023 2024 2025 2026 2027 2028 2029
Revenue
YoY % growth
CVKD revenue by date.CVKD revenue by date.
N/AN/AN/AN/AN/A
EBITDA
YoY % growth
CVKD ebitda by date.CVKD ebitda by date.
N/A-2.7M-7.631M
-182.62%		-10.959M
-43.61%		N/A
-58.23%		N/A
-22.94%		N/A
-44.50%		N/A
-22.85%		N/A
EBIT
YoY % growth
CVKD ebit by date.CVKD ebit by date.
-2.7M-7.633M
-182.70%		-10.961M
-43.60%		N/A
-19.12%		N/A
-17.19%		N/A
-10.00%		N/A
-124.85%		N/A
347.61%
Operating Margin
CVKD operating margin by date.CVKD operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
CVKD eps by date.CVKD eps by date.
N/AN/AN/A-8.67
6.34%		N/A
25.18%		N/A
52.83%		N/A
100.80%		N/A
-13,183.33%		N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-1.19
56.63%		-1.36
35.09%		-1.42
24.18%		-1.54
-17.57%		-1.25
-5.58%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		-4.794M
-12.10%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-2.448M
42.78%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CVKD Yearly Revenue VS EstimatesCVKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 20M 40M 60M 80M 100M
CVKD Yearly EPS VS EstimatesCVKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 0 -2 -4 -6 -8

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
26.05%
EPS Next 5 Year
13.00%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-47.56%
EBIT Next 5 Year
-40.95%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CADRENAL THERAPEUTICS INC / CVKD Forecast FAQ

What is the average price target for CADRENAL THERAPEUTICS INC (CVKD) stock?

7 analysts have analysed CVKD and the average price target is 34.68 USD. This implies a price increase of 539.85% is expected in the next year compared to the current price of 5.42.

When does CADRENAL THERAPEUTICS INC (CVKD) report earnings?

CADRENAL THERAPEUTICS INC (CVKD) will report earnings on 2026-05-06.

Can you provide the consensus estimates for CADRENAL THERAPEUTICS INC next earnings?

The consensus EPS estimate for the next earnings of CADRENAL THERAPEUTICS INC (CVKD) is -1.19 USD and the consensus revenue estimate is 0 USD.